Phelps Brand Welcomes World Champion Swimmer Penny Oleksiak as Global Brand Ambassador
8.10.2020 18:00:00 EEST | Business Wire | Press release
Phelps Brand today announced Canada’s youngest World Champion swimmer Penny Oleksiak is joining the team as an official global ambassador. As part of the Phelps Team, Oleksiak will train and compete utilizing the industry-leading range of products from training equipment to performance swim suits, including the FINA-approved Matrix Technical suit, which is available now to consumers worldwide at www.michaelphelps.com.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201008005297/en/
Michael Phelps welcomes World Champion swimmer Penny Oleksiak to the Phelps Brand. Photo courtesy of Phelps Brand.
Oleksiak, a World Champion swimmer and Olympic-record holder, has been tapped as the face of the Matrix campaign, the Phelps Brand’s first new product launch in 2020. As part of the Phelps Team, Oleksiak (CAN) will help advance the brand globally alongside the growing roster of elite athletes including World Champion and American-record holder Chase Kalisz (USA), two-time Olympian Georgia Davies (UK), French-record holder David Aubry (FRA) and Olympian Luca Pizzini (IT).
“I’m a big fan of Penny and what she’s been able to accomplish in the pool. I’m thrilled she is joining the Phelps Team as the first female global ambassador,” said Phelps. “Penny is a tremendous athlete who shares my passion for the sport and has already provided a lot of great insights for the Phelps Brand. Her personality, talent and confidence are huge assets for the entire swimming community.”
A four-time Olympic medalist and six-time World Championship medalist, Oleksiak is a force on Team Canada. As Canada’s youngest Olympic gold medalist, she holds the nation’s record for most Olympic medals at a single summer games. In her short career she has become known for her exciting come from behind victories, winning four Olympic and six World medals; and currently holds the Olympic Record for the 100 Freestyle.
“I am so excited to be part of the Phelps Team,” said Oleksiak. “I have looked up to Michael my entire career and now have the chance to learn from and work alongside him to bring an incredible experience and line of products to the swimming community. It really is a dream come true for me.”
The Phelps Brand, which originally launched as MP Brand in 2015, continues to develop technologically advanced racing and training suits for competitive swimmers under the direction of Michael Phelps and Hall of Fame coach Bob Bowman.
The first product to launch under the Phelps Brand is the Matrix Tech Suit, a top-of-the-line FINA-approved competitive tech suit created with propriety Exo-Core technology. The Matrix features both adaptive compression material to reduce muscle vibration and drag while ensuring maximum flexibility and freedom of movement. In addition, the Matrix includes a sustaining tape system for improved body position by utilizing front and back axis tape and cross-coordinating to improve length and position.
“Penny is a tremendous athlete and her unique experiences and insights will play a key role in helping inform the competitive swim product innovation in the Phelps Brand today,” said Andrew Gritzbaugh, General Manager of North America for Aqua Lung, the parent company of Phelps Brand and Aqua Sphere. “We’re very excited to welcome her to the team and look forward to supporting her in her future endeavors.”
To purchase Phelps Brand products go to www.michaelphelps.com.
About PHELPS BRAND
The Phelps Brand offers best-in-class, innovative swim products that are inclusive and accessible to a broad range of swimmers across the competitive swimming lifecycle. Combining Aqua Sphere’s global product design expertise and distribution with Michael Phelps’ and Coach Bob Bowman’s experiences at the highest levels of swim performance, the Phelps Brand features technical swim products leveraging proprietary technologies and performance enhancing designs. For more information, visit www.michaelphelps.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005297/en/
Contact information
Lindsay Goodson
lgoodson@aqualung.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom